🇺🇸 FDA
Pipeline program

idursulfase-IT

HGT-HIT-094

Phase 3 mab active

Quick answer

idursulfase-IT for Hunter Syndrome is a Phase 3 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 4 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Hunter Syndrome
Phase
Phase 3
Modality
mab
Status
active

Clinical trials